Brief: T2 Biosystems Sees FY 2023 Total Sepsis & Related Product Rev Of $9.5 Mln To $10.5 Mln
12/07/2023 13:09
July 12 (Reuters) - T2 Biosystems Inc TTOO.O :
* T2 BIOSYSTEMS - EXPECTS FY 2023 TOTAL SEPSIS & RELATED
PRODUCT
REVENUE OF $9.5 MILLION TO $10.5 MILLION, REPRESENTING GROWTH OF
13% TO 25%, VERSUS $8.4 MILLION IN 2022
* T2 BIOSYSTEMS INC - PRELIM Q2 TOTAL REVENUE OF $2.0
MILLION
Further company coverage: TTOO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on T2 Biosystems
See all newsBrief: T2 Biosystems Announces Intent To Wind Down Operations
Brief: T2 Biosystems Enters Amendment No. 12 To Term Loan Agreement
Brief: T2 Biosystems Announces Exclusive US Agreement With Cardinal Health To Sell Its FDA-Cleared Direct-From-Blood Diagnostics For Rapid Detection Of Sepsis-Causing Pathogens
T2 Biosystems Inc reports results for the quarter ended in June - Earnings Summary
Brief: T2 Biosystems Announces Commercial Expansion Through Malaysia And Indonesia Distributor